Back to Search Start Over

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis.

Authors :
Bronte G
Rolfo C
Passiglia F
Rizzo S
Gil-Bazo I
Fiorentino E
Cajozzo M
Van Meerbeeck JP
Lequaglie C
Santini D
Pauwels P
Russo A
Source :
Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2015 Sep; Vol. 95 (3), pp. 306-17. Date of Electronic Publication: 2015 Apr 11.
Publication Year :
2015

Abstract

Background: Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients.<br />Materials and Methods: Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3-4 (G3-4) hematologic toxicities.<br />Results: Six eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI: 1.883-5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203-2.525) in favor of platinum-based doublets. G3-4 hematological toxicities were also more frequent in this group.<br />Conclusion: This meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.<br /> (Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1879-0461
Volume :
95
Issue :
3
Database :
MEDLINE
Journal :
Critical reviews in oncology/hematology
Publication Type :
Academic Journal
Accession number :
25922216
Full Text :
https://doi.org/10.1016/j.critrevonc.2015.03.010